You are here

Structural & Congenital Heart Disease


Next-day discharge after minimalist transcatheter aortic valve replacement (TAVR) was safe for patients who didn’t experience perioperative complications and was linked to better one-year outcomes versus patients discharged later, according to a single-center study published in JACC: Cardiovascular Interventions.

The American Heart Association (AHA) and American College of Cardiology (ACC) rolled out new guidelines for managing valvular heart disease (VHD) in 2017, marking the second overhaul of VHD recommendations in three years—a move attributable to “extensive new data” that have shaped the way clinicians treat valve disease.

A larger valve option and more appropriate valve sizing using preprocedural imaging may eliminate the previously reported survival disparity between men and women undergoing transcatheter aortic valve replacement (TAVR), a new study in JACC: Cardiovascular Interventions suggests.

Procedures to replace or repair patients’ tricuspid valves (TVs) remain rare but have increased in recent years, according to a study in the Journal of the American College of Cardiology. But despite this increased volume, in-hospital mortality has remained steady at 8.8 percent.

The Centera transcatheter heart valve (THV) shows promise in addressing the “Achilles’ heel” of transcatheter aortic valve replacement (TAVR), according to Luis Nombela-Franco, MD, PhD, who wrote an editorial about the device’s pivotal study published in the Journal of the American College of Cardiology.


Recent Headlines

Boston Scientific delays plans to reintroduce LOTUS valve to European market

Plans to reintroduce the troubled LOTUS Edge Aortic Valve System into the European market have stalled, Boston Scientific reported Tuesday.

Paravalvular regurgitation rates slashed with SAPIEN 3 heart valves

The mortality risk associated with moderate to severe PVR was consistent with previous studies, wrote lead author Philippe Pibarot, DVM, PhD, and colleagues, but the rate of moderate or worse PVR dropped threefold when compared to previous SAPIEN valves.

Pediatric heart patients let down by scarcity of quality research

Children suffering from congenital heart disease worldwide are being let down by a paucity of research on their conditions, a review published in the European Journal of Cardio-Thoracic Surgery reports.

Proving the cost-effectiveness of TAVR

When it comes to TAVR, what is good for patients is good for economics too. Or more specifically, what is good for Medicare patients with severe aortic stenosis at intermediate risk for surgery is good for reductions in U.S healthcare costs. The amount depends on where you live, with CMS reimbursing much higher on the East and West Coasts versus the center of the country with valve costs remaining the same.

Mechanical heart valves associated with greater long-term survival for most age groups

Patients who received a mechanical prosthesis for surgical replacement of aortic or mitral valves derived a significant long-term survival benefit versus those who received a biologic prosthesis, according to a study in the New England Journal of Medicine.

Half of U.S. valve hospitals misclassified as low- or high-performing

Nearly half of all valve hospitals in the U.S. are misclassified as either low- or high-performing, according to research published in JAMA Cardiology—but that problem might have a simple fix.

TCT 2017: TAVR ‘economically dominant’ over SAVR for aortic stenosis patients at intermediate risk

DENVER — Transcatheter aortic valve replacement (TAVR) is an “economically dominant” strategy compared to surgical aortic valve replacement (SAVR) for patients with aortic stenosis at intermediate surgical risk, according to data presented by David J. Cohen, MD, MSc, Oct. 31 at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

TCT 2017: Drug-eluting balloon shown non-inferior to drug-eluting stent

Research examining 278 patients with in-stent restenosis (ISR) found that drug-eluting balloon (DEB) was non-inferior in comparison with drug-eluting stent (DES) in terms of six-month minimal lumen diameter (MLD).

TCT 2017: Frailty provides prognostic value for TAVR patients—but better risk scores are needed

DENVER — Measuring frailty could lead to more accurate predictions of outcomes following transcatheter aortic valve replacement (TAVR) than a validated risk algorithm, according to research presented Oct. 30 at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Heart surgeries performed later in the day linked to better outcomes

The time of day a patient receives open-heart surgery could impact their postoperative outcomes, according to a new study in The Lancet.